GA-ENTERSEKT
11.1.2023 12:27:43 CET | Business Wire | Press release
Entersekt, a global leader in customer and payment authentication solutions for financial fraud prevention, today announced the appointment of Jon Roskill, former Acumatica CEO and Microsoft executive, to its board of directors as part of its continued expansion within North America. In late 2021, Entersekt received significant funding from Accel-KKR, a technology-focused private equity firm, to hire key leadership, launch new branding, and accelerate the expansion within this region.
Jon Roskill joins Entersekt board of directors
A former Corporate Vice President at Microsoft, and CEO of Acumatica, Mr. Roskill brings decades of executive and advisory experience to the Entersekt board as the company continues to introduce advanced customer and payment authentication solutions into the North American market as part of its global expansion. He currently serves as a Senior Advisor with EQT Partners after spending eight years with Acumatica, a cloud ERP provider.
“Jon joins our board of directors at a critical time. Entersekt is at an inflection point in our growth and expansion, particularly in North America,” said Schalk Nolte, CEO of Entersekt. “His vast experience in global go-to-market strategies will bring tremendous value to the company.”
“Entersekt has a tremendous opportunity ahead of it, and I’m excited to be joining at such a pivotal time in its growth” added Roskill. “With proven, patented technologies, excellent leadership, a strong, global customer base and solid financial foundation, I look forward to being a part of Entersekt’s next phase as it establishes itself as a global leader in financial fraud prevention.”
Expansion of the leadership team to drive bullish growth strategy
In addition, Entersekt has also hired new additions to the management team to support and accelerate the speed to market of Context Aware™ Authentication in North America. Key hires include Matt Loos as Chief Revenue Officer, Pradheep Sampath as Chief Product Officer and Frank Moreno as Chief Marketing Officer.
The new team brings with them the following strong leadership experience in the financial services industry:
- Loos joins Entersekt with over 20 years of leadership experience at companies like Fifth Third Bank and Mastercard.
- Sampath holds a 25-year track record in scaling SaaS, mobile and API-based products for companies like ID.me and GXS.
- Moreno’s experience includes senior marketing leadership roles spanning over 20 years with companies such as Bottomline and Datawatch.
New strategic partnerships as global growth enablers
Many new integrations and partnerships with strategic technology providers are currently underway. Most recently, Entersekt’s biometric authentication technology was integrated into Q2’s Digital Banking Platform. Q2 is a leading provider of digital transformation solutions for banking and lending. By supporting pre-integration, these partnerships enable banks to quickly and easily deploy Entersekt’s state-of-the-art authentication technology.
Targeting the demand for enhanced security
A recent Forrester Survey of 300 North American fraud prevention decision-makers, reported that all respondents had experienced authentication fraud in the past year. “The investment from Accel-KKR will support the significant market opportunity and demand for the cloud-first, global authentication solutions that Entersekt is known for. We have a strong leadership team in place that will play a critical role in accelerating our business vision to expand and scale into this territory”, concludes Nolte.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom